Doma perpetual nominates three highly qualified candidates for the board of pacira biosciences

Pacira's stock is down 76% over the last decade, while the board and management have enriched themselves at a cost of half a billion dollars, roughly 50% of the current market cap under ceo and board member frank lee, the stock price has declined 33%; he is pushing for higher compensation packages for management while burdening shareholders with new risks; doma believes his views on capital allocation are misaligned with shareholder interest and he has no track record of creating shareholder value change to the board's composition is critical to accelerate shareholder return and to correct a decade of corporate abuse and lack of stock price returns doma's three highly qualified nominees possess vast experience in strategic capital allocation, risk management, healthcare banking and intellectual property law and litigation miami , march 14, 2025 /prnewswire/ -- doma perpetual capital management llc ("doma perpetual") is a fundamentals-based, value-oriented investor that, together with the other participants in its solicitation (collectively "doma" or "we"), beneficially owns approximately 4.2% of the outstanding shares of common stock of pacira biosciences (nasdaq: pcrx) ("pacira" or the "company").i doma today announced its nomination of three highly skilled director candidates to pacira biosciences board of directors (the "board"): joseph kromholz, philip pucciarelli and eric de armas. doma believes electing these nominees is critical to address the board's lack of financial sophistication and legal expertise and to correct its value-destroying capital allocation strategy.
DOMA Ratings Summary
DOMA Quant Ranking